Advances in Colorectal Cancer Screening Strategies in Clinical Practice

In this episode title, ‘Shifting Epidemiology and Risk Factors in Colorectal Cancer,’ the moderator introduces the evolving landscape of colorectal cancer screening and highlights the growing importance of early detection.

The expert faculty explore how clinicians approach rectal bleeding and surveillance decisions in colorectal cancer screening.

In ’Shared Decision-Making in Colorectal Cancer Screening’, the panelists focus on practical strategies for engaging patients in colorectal cancer screening conversations and improving screening uptake.

In ’Shared Decision-Making in Colorectal Cancer Screening’, the panelists focus on practical strategies for engaging patients in colorectal cancer screening conversations and improving screening uptake.

In this episode, ‘Comparing Colorectal Cancer Screening Test Performance and Prep Options,’ the panelists review the performance characteristics of available colorectal cancer screening modalities, including colonoscopy, FIT, multi-target stool DNA, RNA-based tests, and blood-based assays.

In ‘Overcoming Barriers and Advancing Precision in Colorectal Cancer Screening,’ our experts delve into the ongoing challenges and future directions in colorectal cancer screening implementation.

This episode, titled ‘Individualizing When to Stop Colorectal Cancer Screening,’ examines the nuanced decision-making involved in determining when to discontinue colorectal cancer screening.

In this episode, ‘Addressing Access Barriers in Colorectal Cancer Screening,’ the panelists explore common patient concerns about the cost of colonoscopy following a positive colorectal cancer screening test.

In ‘Coordinating Care After Abnormal Colorectal Cancer Screening Results,’ the expert faculty focus on the critical importance of timely follow-up after a positive colorectal cancer screening test.

In the final episode, ‘Key Takeaways in Colorectal Cancer Screening,’ the faculty emphasize that while colonoscopy remains the gold standard, noninvasive stool-based tests are appropriate alternatives for average-risk patients who decline invasive screening.